Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Barclays

Stock analysts at Barclays began coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Get Rating) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set an “overweight” rating and a $20.00 price target on the stock. Barclays‘s target price suggests a potential upside of 133.64% from the company’s current price.

Other research analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $53.00 price target on shares of Nurix Therapeutics in a research note on Friday, February 10th. SVB Leerink decreased their price objective on Nurix Therapeutics from $37.00 to $28.00 and set an “outperform” rating for the company in a report on Tuesday, December 13th. Stifel Nicolaus cut their target price on Nurix Therapeutics from $37.00 to $31.00 and set a “buy” rating on the stock in a research note on Tuesday, February 14th. Needham & Company LLC dropped their price target on Nurix Therapeutics from $32.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, February 10th. Finally, Royal Bank of Canada decreased their target price on Nurix Therapeutics from $39.00 to $30.00 and set an “outperform” rating for the company in a report on Friday, February 10th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.75.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $8.56 on Thursday. Nurix Therapeutics has a fifty-two week low of $7.52 and a fifty-two week high of $19.91. The firm has a market cap of $404.63 million, a price-to-earnings ratio of -2.29 and a beta of 1.72. The business has a 50-day simple moving average of $10.85 and a two-hundred day simple moving average of $12.22.

Hedge Funds Weigh In On Nurix Therapeutics

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of Nurix Therapeutics by 11.0% during the third quarter. BlackRock Inc. now owns 3,723,090 shares of the company’s stock worth $48,512,000 after purchasing an additional 367,743 shares in the last quarter. State Street Corp grew its holdings in shares of Nurix Therapeutics by 9.2% during the third quarter. State Street Corp now owns 2,312,224 shares of the company’s stock valued at $30,128,000 after purchasing an additional 195,453 shares during the last quarter. Vanguard Group Inc. grew its holdings in Nurix Therapeutics by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company’s stock worth $28,156,000 after buying an additional 49,370 shares in the last quarter. ARK Investment Management LLC grew its holdings in Nurix Therapeutics by 54.5% in the 4th quarter. ARK Investment Management LLC now owns 1,988,254 shares of the company’s stock worth $21,831,000 after buying an additional 701,732 shares in the last quarter. Finally, Bain Capital Life Sciences Investors LLC grew its holdings in Nurix Therapeutics by 41.9% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 1,822,883 shares of the company’s stock worth $23,096,000 after buying an additional 538,570 shares in the last quarter. 91.33% of the stock is owned by institutional investors and hedge funds.

Nurix Therapeutics Company Profile

(Get Rating)

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.